LadRx is a clinical-stage biopharmaceutical company with two full-time employees developing targeted cancer therapies. Its core technology, called LADR (Linker Activated Drug Release), attaches potent chemotherapy drugs to a small organic molecule that binds to albumin, a protein that naturally accumulates in solid tumors. This allows the drug to concentrate inside tumors and release its payload in the tumor's acidic environment, with the goal of reducing the toxic side effects of conventional chemotherapy on healthy organs. LadRx's lead candidate is aldoxorubicin, a modified version of doxorubicin attached to the LADR backbone, which has been tested in over 600 patients and holds FDA Orphan Drug Designation for soft tissue sarcoma, ovarian cancer, pancreatic cancer, and non-small cell lung cancer. LadRx is pursuing FDA approval for aldoxorubicin via the 505(b)(2) pathway, which allows it to rely on doxorubicin's existing safety record to reduce regulatory burden. LadRx also has four next-generation candidates — LADR-7, 8, 9, and 10 — combining the next-generation backbone with ultrapotent chemotoxins. LadRx has no approved products or product revenue, and its survival depends on raising additional capital. LadRx sold its royalty and milestone rights to aldoxorubicin to XOMA in 2023, giving XOMA a permanent economic interest in any future commercial success. LadRx has not decided whether to commercialize aldoxorubicin directly or license it to a partner.